The present invention relates to a process for preparing Lomitapide or its pharmaceutically acceptable salt thereof having high purity with acceptable levels of impurities.
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
C07D 211/58 - Nitrogen atoms attached in position 4
C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
C07C 67/293 - Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by isomerisationPreparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by change of size of the carbon skeleton
C07C 69/157 - Acetic acid esters of monohydroxylic compounds of unsaturated alcohols containing six-membered aromatic rings
C07C 51/367 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in singly bound form
C07C 62/32 - Unsaturated compounds containing hydroxy or O-metal groups
The present invention relates to a process for preparing Lomitapide or its pharmaceutically acceptable salt thereof having high purity with acceptable levels of impurities.
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
C07D 211/58 - Nitrogen atoms attached in position 4
C07C 67/293 - Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by isomerisationPreparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by change of size of the carbon skeleton
C07C 69/157 - Acetic acid esters of monohydroxylic compounds of unsaturated alcohols containing six-membered aromatic rings
C07C 51/367 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in singly bound form
C07C 62/32 - Unsaturated compounds containing hydroxy or O-metal groups
3.
Process for the preparation of intermediate of dolutegravir
The present invention provides a novel processes for preparation of methyl 3-(benzyloxy)-5-(2,4-difluorobenzylcarbamoyl)-4-oxo-1-(2-oxoethyl)-1,4-dihydropyiridine-2-carboxylate using novel intermediates.
C07D 213/02 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
C07D 213/14 - Preparation from compounds containing heterocyclic oxygen
C07D 231/46 - Oxygen atom in position 3 or 5 and nitrogen atom in position 4
C07C 201/12 - Preparation of nitro compounds by reactions not involving the formation of nitro groups
C07D 231/08 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
The present invention provides a novel process for the preparation of pomalidomide crystalline Form I. The present invention also provides a process for the purification of pomalidomide.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention provides novel polymorphs of Lomitapide, process for their preparation and pharmaceutical compositions comprising them. The present invention also provides a novel polymorph of Lomitapide mesylate, process for its preparation and pharmaceutical compositions comprising it.
The present invention provides an improved process for the preparation of 4α-acetoxy-2α-benzoyloxy-5β,20-epoxy-1β,13α-dihydroxy-7β,10β-dimethoxy-9-oxo-11-taxene (7β,10β-dimethoxy-10-deacetoxybaccatin III). The present invention also provides a novel process for the preparation of cabazitaxel.
C07D 305/14 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
The present invention relates to a process for the preparation of Ledipasvir using Bis(triphenylphosphine)palladium(II) dichloride and process for the preparation of intermediates of Ledipasvir.
A61K 31/00 - Medicinal preparations containing organic active ingredients
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present invention provides processes for the preparation of i) Regorafenib (4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide, BAY 73-4506, Stivarga®) and its pharmaceutically acceptable salt thereof; ii) a crystalline solid of Regorafenib tosylate; iii) Regorafenib Polymorph I from Regorafenib tosylate, and iv) a pure 4-(4-amino-3-fluorophenoxy)-N-methylpicolinamide from 4-amino-3-fluorophenol and 4-chloro-N-methylpicolinamide in the presence of potassium tert-butoxide.
The present invention relates to compositions of eltrombopag olamine. The present invention also relates to process for preparing compositions comprising eltrombopag olamine.
The present invention relates to a process for preparing Lomitapide or its pharmaceutically acceptable salt thereof having high purity with acceptable levels of impurities.
C07C 33/34 - Monohydroxylic alcohols containing six-membered aromatic rings and other rings
C07C 209/08 - Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of halogen atoms with formation of amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
C07C 209/74 - Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by halogenation, hydrohalogenation, dehalogenation, or dehydrohalogenation
C07C 29/09 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis
C07C 61/29 - Unsaturated compounds polycyclic having a carboxyl group bound to a condensed ring system
The present invention relates to novel betulinic proline imidazole derivatives and related compounds, compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
C07J 63/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
14.
NOVEL BETULINIC PROLINE SUBSTITUTED DERIVATIVES AS HIV INHIBITORS
The invention relates to novel betulinic proline substituted derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases. Formula (I)
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
15.
EXTENDED RELEASE COMPOSITIONS OF CARVEDILOL PHOSPHATE
The present invention relates to solid oral dosage forms of carvedilol phosphate. More specifically, the present invention relates to extended release compositions of carvedilol phosphate and process for their preparation.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
The present invention provides a novel amorphous solid dispersion of linagliptin in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
The present invention provides a novel process for the purification of alpha-propargylhomoterephthalic acid dimethyl ester substantially free of homoterephthalic acid dimethyl ester. The present invention also provides a novel process for the purification of pralatrexate.
C07C 67/52 - SeparationPurificationStabilisationUse of additives by change in the physical state, e.g. crystallisation
C07C 67/343 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisationPreparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by change of size of the carbon skeleton by increase in the number of carbon atoms
C07D 475/08 - Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
The present invention relates to liquid compositions of asenapine with one or more pharmaceutically acceptable excipients. More particularly, the present invention relates to liquid spray compositions comprising asenapine for administration through oral mucosa.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
The present invention provides novel polymorphs of Lomitapide, process for their preparation and pharmaceutical compositions comprising them. The present invention also provides a novel polymorph of Lomitapide mesylate, process for its preparation and pharmaceutical compositions comprising it.
The present invention relates to parenteral compositions of bendamustine. More particularly, the present invention relates to parenteral compositions of bendamustine in the form of solution.
The present invention provides a commercially viable process for preparing rilpivirine and its pharmaceutically acceptable acid addition salts thereof in high yields using novel intermediate.
The present invention provides a solid dispersion of rufinamide in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
The present invention provides processes for the preparation of i) Regorafenib (4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl} amino)-3-fluorophenoxy] -N-methylpyridine-2-carboxamide, BAY 73-4506, Stivarga®) and its pharmaceutically acceptable salt thereof; ii) a crystalline solid of Regorafenib tosylate; iii) Regorafenib Polymorph I from Regorafenib tosylate, and iv) a pure 4-(4-amino-3-fluorophenoxy)-N-methylpicolinamide from 4-amino-3-fluorophenol and 4-chloro-N-methylpicolinamide in the presence of potassium tert-butoxide.
The present invention provides novel crystalline hydrochloride salt of darunavir, process for its preparation and to pharmaceutical composition comprising it. The present invention also provides novel process for preparation of darunavir amorphous form and pharmaceutical composition comprising it.
C07D 307/93 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
27.
PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST AND PROCESS FOR PREPARATION THEREOF
The present invention relates to pharmaceutical compositions of roflumilast. More particularly, the present invention relates to pharmaceutical tablet compositions of roflumilast and process for preparing the same.
The present invention relates to compositions of eltrombopag olamine. The present invention also relates to process for preparing compositions comprising eltrombopag olamine.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention provides a novel processes for preparation of methyl 3- (benzyloxy)-5-(2,4-difluorobenzylcarbamoyl)-4-oxo-l-(2-oxoethyl)-l,4-dihydropyiridine-2- carboxylate using novel intermediates.
This invention discloses the method of preparation of 4alfa.acetoxy-2alfa-benzoyloxy-5beta,20-epoxy-1beta,13alfa-dihydroxy-7beta, 10beta-dimethoxy-9-oxo-11-taxen (7beta, 10beta-dimethoxy-10-deacetoxybaccatin III) and the preparation of cabazitaxel, which comprises: a. dissolving (2aR,4S,4aS,6R,9S, 11S.I2S, 12aR, 12bS)-12b-acetoxy-9- (( (2R,3 S)-3-amino-2-hydroxy-3-phenylpropanoyl)oxy)-1 I-hydroxy-4,6-dimethoxy-4a,8, 13, 13-tettamethyl-5-oxo-2a, 3,4,4a, 5,6,9, 10, 1 1,12, 12a, 12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[l,2-b]oxet-12-yl benzoate.
The present invention provides a novel crystalline Form of vismodegib, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides a novel amorphous Form of vismodegib, process for its preparation and pharmaceutical compositions comprising it.
C07D 403/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
The present invention provides a novel process for the preparation of rilpivirine. The present invention also provides a novel process for the preparation of rilpivirine hydrochloride. The present invention further provides a rilpivirine hydrochloride monohydrate, process for its preparation and pharmaceutical compositions comprising it.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence
C07F 9/6512 - Six-membered rings having the nitrogen atoms in positions 1 and 3
The present invention provides a novel process for the preparation of pomalidomide crystalline Form I. The present invention also provides a process for the purification of pomalidomide.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 307/89 - Benzo [c] furansHydrogenated benzo [c] furans with two oxygen atoms directly attached in positions 1 and 3
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
The present invention relates to solid dosage form comprising febuxostat or a pharmaceutically acceptable salt thereof. Particularly, the present invention relates to tablet compositions of febuxostat and process for their preparation.
The present invention provides a novel process for the preparation of 4-(4-hydroxypyrimidin-2-ylamino)benzonitrile. The present invention also provides a novel process for the preparation of 4-iodo-2,6-dimethyl benzenamine. The present invention further provides an improved process for the preparation of rilpivirine. The present invention further provides a tosylate salt of rilpivirine, process for its preparation and pharmaceutical compositions comprising it.
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
C07C 209/74 - Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by halogenation, hydrohalogenation, dehalogenation, or dehydrohalogenation
The present invention relates to pharmaceutical compositions of saxagliptin. Particularly, the present invention relates to tablet compositions of saxagliptin and process for their preparation.
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
The present invention provides a novel amorphous solid dispersion of ticagrelor in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it. Specifically, provided is a process for the preparation of amorphous solid dispersion of ticagrelor which comprises: a) preparing a solution comprising a mixture of ticagrelor and one or more pharmaceutically acceptable carriers selected from copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus in a solvent; and b) removing the solvent to obtain amorphous solid dispersion of ticagrelor in the carrier.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
The present invention provides a compound of crizotinib oxalate salt, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides a novel process for the preparation of crizotinib using novel intermediate. The present invention further provides a process for the purification of crizotinib. The present invention further provides a novel amorphous solid dispersion of crizotinib in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
The present invention provides a novel amorphous solid dispersion of carvedilol phosphate in combination with a pharmaceutically acceptable carrier and, process for its preparation. The present invention also provides pharmaceutical compositions comprising a therapeutically effective amount of amorphous solid dispersion of carvedilol phosphate along with a pharmaceutically acceptable carrier and at least one pharmaceutically acceptable excipient.
The present invention provides novel solvated forms of darunavir and processes for their preparation. The present invention also provides novel processes for the preparation of darunavir amorphous form and pharmaceutical compositions comprising it. Thus, for example, darunavir 2-methyl-2-butanol solvate was dissolved in methylene dichloride, distilled under vacuum at 45° C. to obtain a residue, cyclohexane was added to the residue and stirred for 30 hours at 20 to 25° C., and the separated solid was filtered, washed with cyclohexane and dried under vacuum at 50° C. for 12 hours to yield darunavir amorphous form.
A01N 43/08 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom five-membered rings with oxygen as the ring hetero atom
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
C07D 493/00 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
The invention relates to novel betulinic acid derivatives and related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases. These compounds are esterified in position 3 and are substituted in position 17 of the betulinic acid structure, via a linking group W, by a saturated 5-7 membered nitrogen-heterocycle.
C07J 63/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
The present invention provides a novel amorphous solid dispersion of saxagliptin hydrochloride in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it. The present invention provides pharmaceutical compositions comprising a therapeutically effective amount of amorphous solid dispersion of saxagliptin hydrochloride along with a pharmaceutically acceptable carrier, and at least one pharmaceutically acceptable excipient
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
The present invention provides a novel process for the preparation of abiraterone. The present invention also provides a novel process for the preparation of abiraterone acetate. In one aspect, the present invention provides a novel process for the preparation of abiraterone, which comprises: a) reacting dehydroepiandrosterone-3-acetate in a chlorinated solvent with trifluoromethanesulfonic anhydride in the presence of a base selected from the group consisting of n-methylpyrrolidone, N-methylpiperidine or tetramethylethylenediamine in a chlorinated solvent.
C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
The present invention provides a novel process for the purification of lurasidone substantially free of isomeric impurity. According to on aspect of the present invention, there is provided a novel process for the purification of lurasidone substantially free of isomeric impurity which comprises crystallizing the lurasidone substantially free of isomeric impurity from a solution of lurasidone containing isomeric impurity in an ester solvent or a chlorinated solvent.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
The present invention provides a novel amorphous solid dispersion of lurasidone hydrochloride in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
The present invention provides a novel process for the purification of alpha-propargylhomoterephthalic acid dimethyl ester substantially free of homoterephthalic acid dimethyl ester. The present invention also provides a novel process for the purification of pralatrexate.
The disclosure is related to amorphous raltegravir and the solid oral dosage forms of amorphous raltegravir that are of lower dosage than the commercially available reference dosage form. Provided herein are a pharmaceutical solid oral dosage form composed from (a) 300 mg of amorphous raltegravir or an equivalent amount of a pharmaceutically acceptable salt thereof; (b) a polymer; and (c) a pharmaceutically acceptable excipient and a method of reducing adverse effects of raltegravir administration in a human subject, comprising administering to the human subject a solid oral dosage form comprising 300 mg of amorphous raltegravir or an equivalent amount of a pharmaceutically acceptable salt thereof.
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
The present invention relates to amorphous ritonavir co-precipitated on copovidone, process for its preparation and pharmaceutical compositions comprising it.
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 277/28 - Radicals substituted by nitrogen atoms
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
The present invention provides a novel amorphous Form of azilsartan acid, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides novel crystalline Forms of azilsartan medoxomil, processes for their preparations and pharmaceutical compositions comprising them. The present invention further provides a novel amorphous Form of azilsartan medoxomil potassium, process for its preparation and pharmaceutical compositions comprising it. The present invention further provides a novel process for the preparation of azilsartan medoxomil potassium crystalline Form II.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The present invention relates to pharmaceutical compositions comprising rufinamide premix and one or more pharmaceutically acceptable excipients and methods of preparing the same. Chemically rufinamide is 1-[ (2,6-difluorophenyl)methyl]-IHI,2,3-triazole-4 carboxamide. It has a molecular formula C10H2F2N4) molecular weight of 238.2, and structural Formula I.
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
The present invention provides a novel amorphous Form of doxercalciferol, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides a solid dispersion of doxercalciferol in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it. The present invention further provides a novel crystalline Form of doxercalciferol, process for its preparation and pharmaceutical compositions comprising it.
C07C 401/00 - Irradiation products of cholesterol or its derivativesVitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
The present invention provides a novel amorphous form of vildagliptin, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides a solid dispersion of vildagliptin in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it. Vildagliptin (LAF237) is an oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs.
The present invention provides a solid dispersion of rufinamide in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it. The present invention provides a solid dispersion of rufinamide in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
The present invention provides a novel amorphous solid dispersion of linagliptin in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it. The present invention provides a novel amorphous solid dispersion of linagliptin in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
C07D 473/04 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
The present invention provides a commercially viable process for preparing rilpivirine and its pharmaceutically acceptable acid addition salts thereof in high yields using novel intermediate. Rilpivirine (TMC278) is an investigational new drug, developed by Tibotec, for the treatment of HIV infection. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTis.
The present invention provides a novel crystalline form of azilsartan acid, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides a novel crystalline form of azilsartan medoxomil potassium, process for its preparation and pharmaceutical compositions comprising it. Azilsartan medoxomil is chemically (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl-2-ethoxy-1-([2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl)-1 H-benzimidazole-7-carboxylate. Azilsartan is an angiotensin II receptor antagonist used in the treatment of hypertension.
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
The present disclosure relates to solid oral compositions of silodosin or its pharmaceutically acceptable salt thereof. More particularly, capsule compositions of silodosin with one or more pharmaceutically acceptable excipients and process for their preparation. In a first embodiment, a solid oral composition is discosed comprising: i) silodosin, ii) sodium stearyl fumarate as lubricant, and iii) one or more pharmaceutically acceptable excipients.
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
Stable pharmaceutical compositions of fesoterodine or its pharmaceutically acceptable salt thereof and process for preparing the same. In a first embodiment, a stable pharmaceutical composition is provided comprising fesoterodine fumarate, glyceryl behenate and a stabilizer. The stable pharmaceutical tablet composition may further comprise i) fesoterodine fumarate in an 5 amount of 1% to 5% by weight, ii) glyceryl behenate in an amount of 1% to 8% by weight, iii) pregelatinized starch in an amount of 30% to 50% by weight and iv) a stabilizer in an amount of 0.1 % to 10% by weight based on total weight of the composition.
The present invention provides a novel substantially amorphous solid dispersion of ibandronate sodium in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it. In a preferred embodiment the process for the preparation of amorphous solid dispersion of ibandronate sodium in combination with a pharmaceutically acceptable carrier comprises: preparing a solution comprising a mixture of ibandronate sodium and one or more pharmaceutically acceptable carriers selected from copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol, span 20 or soluplus in a solvent, water or mixture thereof; and removing the solvent or water to obtain substantially amorphous solid dispersion of ibandronate sodium in combination with a pharmaceutically acceptable carrier.
The present invention provides a novel amorphous solid dispersion of elvitegravir in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it. In a preferred embodiment the process for the preparation of amorphous solid dispersion of elvitegravir in combination with a pharmaceutically acceptable carrier comprises: preparing a solution comprising a mixture of elvitegravir and one or more pharmaceutically acceptable carriers selected from copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol, span 20 or soluplus in a solvent; and removing the solvent from the solution obtained; adding hydrocarbon solvent to the residual solid; and isolating amorphous solid dispersion of elvitegravir in combination with a pharmaceutically acceptable carrier.
The present invention provides a novel process for the preparation of sorafenib tosylate polymorph III. The preferred embodiment for the preparation of sorafenib tosylate polymorph III, comprises: providing a solution comprising sorafenib, p-toluenesulfonic acid and a solvent selected from a group consisting of a mixture of dimethyl acetamide and an alcoholic solvent, a mixture of dimethylformamide and an alcoholic solvent and a mixture thereof; adding an alcoholic solvent to the solution obtained; isolating the solid; slurring the solid with an alcoholic solvent; and isolating sorafenib tosylate polymorph III.
The present invention provides a novel amorphous solid dispersion of saxagliptin in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it. In a preferred embodiment, the process for the preparation of amorphous solid dispersion of saxagliptin in combination with a pharmaceutically acceptable carrier comprises: preparing a solution comprising a mixture of saxagliptin and one or more pharmaceutically acceptable carriers selected from copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus in a solvent; and removing the solvent to obtain amorphous solid dispersion of saxagliptin in combination with a pharmaceutically acceptable carrier.
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
The present invention provides a novel amorphous solid dispersion of desvenlafaxine succinate in combination with soluplus, process for its preparation and pharmaceutical compositions comprising it. In one aspect, the present invention provides amorphous solid dispersion of desvenlafaxine succinate in combination with soluplus. In another aspect, the present invention there is provided a process for the preparation of amorphous solid dispersion of desvenlafaxine succinate in combination with soluplus, which comprises: a) preparing a solution comprising a mixture of desvenlafaxine succinate and soluplus in a solvent; and b) removing the solvent to obtain amorphous solid dispersion of desvenlafaxine succinate in combination with soluplus. Yet in another aspect, the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of amorphous solid dispersion of desvenlafaxine succinate along with soluplus, and at least one pharmaceutically acceptable excipient.
The present invention provides betulinic acid derivatives and related compounds, which may be used as antiviral particularly as anti-HIV compounds and processes for the synthesis of these compounds. Pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, together with pharmaceutically acceptable carriers, excipients or diluents, which can be used for the treatment of diseases, condition and/or disorders mediated by viral infections, are also provided.
The present invention provides a novel amorphous solid dispersion of sunitinib malate in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it. In one aspect, the present invention provides amorphous solid dispersion of sunitinib malate in combination with a pharmaceutically acceptable carrier. In another aspect, the present invention there is provided a process for the preparation of amorphous solid dispersion of sunitinib malate in combination with a pharmaceutically acceptable carrier, which comprises: a) preparing a solution comprising a mixture of sunitinib malate and one or more pharmaceutically acceptable carriers selected form copovidone, span 20, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus in water; and b) subjecting the resulting solution to freeze drying to obtain amorphous solid dispersion of sunitinib malate in combination with a pharmaceutically acceptable carrier.
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
The present invention relates to novel non-hygroscopic anhydrous Form of moxifloxacin hydrochloride, process for its preparation and to pharmaceutical composition containing it.
The present invention provides a compound of 7,8-dimethoxy-3-[3-[[(1S)-(4,5-dimethoxybenzocyclobutan-1-yl)methyl]methylamino]propyl]-1,3-de-hydro-7,8-dimethoxy-2H-3-benzazepin-2-one oxalate (de-hydro ivabradine oxalate salt) and process for its preparation. The present invention also provides a process for the purification of de-hydro ivabradine oxalate salt. The present invention further provides a novel process for the preparation of ivabradine using novel intermediate. The present invention further provides a novel amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
The present invention provides a solid of pitavastatin tert-butyl ester and process for its preparation. The present invention also provides a novel crystalline form of pitavastatin calcium, process for its preparation and pharmaceutical compositions comprising it.
C07D 215/04 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
C07D 215/16 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
The present invention provides a novel amorphous Form of lurasidone hydrochloride, process for its preparation and pharmaceutical compositions comprising it. In one aspect, the present invention provides an amorphous form of lurasidone hydrochloride. In another aspect, the present invention provides a process for the preparation of lurasidone hydrochloride amorphous Form, which comprises: a) dissolving lurasidone hydrochloride in a mixture of alcoholic solvent and water; and b) subjecting the resulting solution to lyophilization to obtain lurasidone hydrochloride amorphous form.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present invention relates to pharmaceutical compositions comprising ritonavir premix, a water soluble polymer and a surfactant and process for preparing the same. The ritonavir premix comprises ritonavir, copovidone, colloidal silicon dioxide and sorbitan monolaurate. More particularly, the present invention relates to hot-melt extrusion process for preparing solid oral compositions of ritonavir premix.
The present invention provides novel crystalline forms of maraviroc phosphate, processes for their preparation and pharmaceutical compositions comprising them. The present invention also provides novel process for the preparation of maraviroc amorphous form and pharmaceutical composition comprising it.
C07D 451/04 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamineCyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropaneCyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring system
The present invention is directed to extended release pharmaceutical compositions comprising nevirapine, a release control polymer/ material and one or more pharmaceutically acceptable excipients, process for its preparation and use in the treatment of HIV-1 infection in adults.
CONTROLLED RELEASE SOLID ORAL COMPOSITIONS OF DEXLANSOPRAZOLE ABSTRACT: The present invention relates to controlled release solid oral compositions of dexlansoprazole or its pharmaceutically acceptable salts and process for preparation thereof and its use for healing of erosive esophagitis, maintenance of healed erosive esophagitis and treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease.
The present invention provides a novel process for the preparation of 7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-5-one. The present invention also provides an improved process for the preparation of 7-chloro-1-(2-methyl-4-nitrobenzoyl)-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine. The present invention further provides an improved process for the preparation of 7-chloro-1-[2-methyl-4-[(2-methylbenzoyl)amino]benzoyl]-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine.
The present invention provides a novel process for the purification of alvimopan. In accordance with the present invention alvimopan was dissolved in dimethylformamide and heated to 120 to 125 deg C, and then added n-butanol at room temperature, the contents were stirred for 15 hours, filtered and then dried to obtain pure alvimopan.
C07D 211/28 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
The present invention is directed to fast release pharmaceutical compositions comprising entecavir or its pharmaceutically acceptable salts, process for preparing the same and use of such compositions for the treatment of Hepatitis B virus infection. In a preferred embodiment, the present invention relates to pharmaceutical composition comprising 0.05-1% by weight of entecavir, 1-6% by weight of acid component, 1-90% by weight of carbonates/ bicarbonates of sodium, magnesium, potassium and calcium and 1-20% by weight of superdisintegrant based on total weight of the composition.
4-[[6-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-benzonitrile is a key intermediate for the preparation of etravirine. The present invention provides a process for preparation of 4-[[6-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile. The present invention also provides a novel process for the preparation of etravirine crystalline form I. The present invention further provides novel crystalline forms of etravirine, processes for their preparation and pharmaceutical compositions comprising them.
The present invention provides a novel process for the preparation of amorphous alogliptin benzoate. The present invention also provides amorphous alogliptin benzoate co-precipitated on copovidone, process for its preparation and pharmaceutical compositions comprising it. The present invention further provides novel salts of alogliptin, processes for their preparation and pharmaceutical compositions comprising them. The present invention further provides crystalline hydrochloride salt of alogliptin, process for its preparation and pharmaceutical compositions comprising it. The present invention further provides crystalline tartrate salt of alogliptin, process for its preparation and pharmaceutical compositions comprising it.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention provides novel crystalline hydrochloride salt of darunavir, process for its preparation and to pharmaceutical composition comprising it. The present invention also provides novel process for preparation of darunavir amorphous form and pharmaceutical composition comprising it.
C07D 493/02 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
C07D 307/93 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
As used herein the term "room temperature" refers to a temperature of about 25°C to about 35°C. According to one aspect of the present invention, there IS provided a novel process for the preparation of rilpivirine, which comprises: a) condensing the (E)-3-( 4-amino-3,5-dimethylphenyl)acrylonitrile hydrochloride with 4-( 4-chloropyrimidin-2-ylamino )benzonitrile m the presence of Nmethylpyrrolidone; b) heating the contents obtained in step (a) at about 75 to 95°C to obtain a solution; c) cooling the solution obtained in step (b) at below 35°C; d) adding water to the reaction mass; and e) isolating rilpivirine. The reaction in step (b) may preferably be heated to 100 to 110°C. Step (c) may preferably be carried out at room temperature. Rilpivirine may be isolated in step (e) by the methods known such as Filtration or centrifugation.
As used herein the term "room temperature" refers to a temperature of about 25°C to about 35°C. According to one aspect of the present invention, there IS provided a novel process for the preparation of rilpivirine, which comprises: a) condensing the (E)-3-( 4-amino-3,5-dimethylphenyl)acrylonitrile hydrochloride with 4-( 4-chloropyrimidin-2-ylamino )benzonitrile m the presence of Nmethylpyrrolidone; b) heating the contents obtained in step (a) at about 75 to 95°C to obtain a solution; c) cooling the solution obtained in step (b) at below 35°C; d) adding water to the reaction mass; and e) isolating rilpivirine. The reaction in step (b) may preferably be heated to 100 to 110°C. Step (c) may preferably be carried out at room temperature. Rilpivirine may be isolated in step (e) by the methods known such as Filtration or centrifugation.
The present invention relates to amorphous mixture of lopinavir and ritonavir coprecipitated on copovidone, process for its preparation and pharmaceutical compositions comprising it. In one aspect, the present invention provides amorphous mixture of lopinavir and. ritonavir co-precipitated on copovidone. In another aspect, the present invention provides a process for the preparation of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone, which comprises: i) dissolving a mixture of lopinavir, ritonavir, copovidone, aerosil and span-20 in an alcoholic solvent; and ii) removing the solvent by drying at about 50 to 80°C to obtain amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
The present invention provides an improved process for the preparation of 3-(benzyloxycarbonylamino)piperidine-2,6-dione. The present invention also provides an improved process for the preparation of 3-(4-nitro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione. The present invention further provides a process for the preparation of lenalidomide crystalline Form H1.
A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
The present invention provides a process for the preparation of 1H-benzimidazol-1-methyl-5-N,N-di(2-hydroxyethyl)-2-butanoic acid ethyl ester. The present invention also provides a process for the preparation of bendamustine hydrochloride. The present invention further provides a process for the purification of bendamustine hydrochloride.
Crystalline Forms of fosamprenavir calcium are disclosed, processes for its preparation and pharmaceutical compositions therefrom. The process for the preparation of fosamprenavir calcium crystalline Form H1, comprises: a) suspending fosamprenavir calcium in a nitrile solvent; b) heating the suspension obtained in step (a) at reflux; c) optionally adding a solvent to the reaction mass obtained in step (b); d) cooling the reaction mass at below 35 degrees Centigrade; and e) isolating fosamprenavir calcium crystalline Form H1. Another process for the preparation of substantially pure amorphous fosamprenavir calcium, which comprises: a) dissolving fosamprenavir calcium in an ester solvent; b) a portion of solvent from the solution obtained in step (a) until at least separation of fosamprenavir calcium as solid occurs; and c) isolating substantially pure amorphous fosamprenavir calcium. The pharmaceutical composition may comprse substantially pure amorphous fosamprenavir calcium and pharmaceutically acceptable excipients.
C07F 9/655 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
The present invention provides a process for the preparation of 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester. The present invention also provides a process for the preparation of 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester. The present invention further provides novel crystalline Forms of febuxostat, processes for their preparation and pharmaceutical compositions comprising them. The present invention further provides febuxostat crystalline particles having a mean particle size of less than about 25 µm, the methods for the manufacture of said crystalline particles, and pharmaceutical compositions comprising said crystalline particles.
In one aspect, the present invention provides amorphous ritonavir co-precipitated on copovidone. In another aspect, the present invention provides a process for the preparation of amorphous ritonavir co-precipitated on copovidone, which comprises: a) dissolving a mixture of ritonavir and copovidone in an alcoholic solvent; and b) removing the solvent by drying at about 50 to 80°C to obtain amorphous ritonavir co-precipitated on copovidone. Yet in another aspect, the present invention provides a pharmaceutical composition comprising amorphous Form of ritonavir co-precipitated on copovidone and pharmaceutically acceptable excipients.
Pharmaceutical compositions comprise nilotinib or a pharmaceutically acceptable salt thereof and a process for the preparation of the same. Methods of using such compositions treat subjects suffering from Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML). A process for preparing dry-granulated pharmaceutical composition of nilotinib comprising compacting nilotinib hydrochloride alone or mixing with one or more of pharmaceutically acceptable excipient(s) by roller compactor or slugging; sizing the compacts or slugs into granules by milling; mixing the granules with one or more of pharmaceutically acceptable excipients to form the composition.
In one aspect, the present invention provides a novel process for reducing palladium content in fosaprepitant dimeglumine, which comprises: a) providing a solution of fosaprepitant dimeglumine in a solvent; b) adding SiliaBond Metal Scavenger to the solution obtained in step (a); c) maintaining the reaction mass obtained in step (b); d) adding a solvent to the reaction mass; e) isolating the wet solid; f) slurring the wet solid obtained in step (e) with an ester solvent; and g) isolating fosaprepitant dimeglumine.
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
Described herein is pure amorphous darunavir, methods of making pure amorphous darunavir and pharmaceutical compositions containing amorphous darunavir and a pharmaceutically acceptable excipient.
A01N 43/08 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom five-membered rings with oxygen as the ring hetero atom
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
Disclosed are pharmaceutical compositions comprising HIV integrase strand transfer inhibitor. More particularly, oral pharmaceutical compositions of raltegravir or its pharmaceutically acceptable salts and process for preparing and use of the same are disclosed.
The present invention provides a novel process for the preparation of 4-(4-hydroxypyrimidin-2-ylamino)benzonitrile. The present invention also provides a novel process for the preparation of 4-iodo-2,6-dimethyl benzenamine. The present invention further provides an improved process for the preparation of rilpivirine. The present invention further provides a tosylate salt of rilpivirine, process for its preparation and pharmaceutical compositions comprising it.
Described herein are pharmaceutical compositions of quetiapine, more particularly extended release compositions of quetiapine or its pharmaceutically acceptable salts comprising carboxymethyl ethyl cellulose, a non-gelling, hydrophobic release controlling polymer, and processes for preparing the same.
The present invention provides a novel process for the preparation of 4-(4-hydroxypyrimidin-2-ylamino)benzonitrile. The present invention also provides a novel process for the preparation of 4-iodo-2,6-dimethyl benzenamine. The present invention further provides an improved process for the preparation of rilpivirine. The present invention further provides a tosylate salt of rilpivirine, process for its preparation and pharmaceutical compositions comprising it.
It has been found that compositions of raltegravir comprising non-gelling polymers are comparable with the marketed raltegravir potassium formulation. In one embodiment, the pharmaceutical composition comprises raltegravir as active ingredient or its pharmaceutically acceptable salt thereof, non-gelling polymer and one or more pharmaceutically acceptable excipients. In anoth embodiment, the pharmaceutical composition comprises raltegravir, non-gelling polymer selected from polymethacrylates and/or polyethylene oxide, and one or more pharmaceutically acceptable excipients, characterized in that said composition is free of anti-nucleating agent.
Disclosed are pharmaceutical compositions comprising HIV integrase strand transfer inhibitor. More particularly, oral pharmaceutical compositions of raltegravir or its pharmaceutically acceptable salts and process for preparing and use of the same are disclosed.
The present invention provides a novel crystalline Form of lenalidomide, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides a novel N-methylpyrrolidone solvate of lenalidomide and process for its preparation.
patents
